Lactate score classification of hepatocellular carcinoma helps identify patients with tumors that respond to immune checkpoint blockade therapy.

Autor: Jiang K; Department of Biobank, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China., Zhu L; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China., Huang H; Department of Gastroenterology, Shanghai General Hospital, Nanjing Medical University, Shanghai, 201620, China., Zheng L; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China., Wang Z; Department of Biobank, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China., Kang X; Department of Biobank, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. kangxiaonan@renji.com.
Jazyk: angličtina
Zdroj: Cellular oncology (Dordrecht) [Cell Oncol (Dordr)] 2024 Feb; Vol. 47 (1), pp. 175-188. Date of Electronic Publication: 2023 Aug 23.
DOI: 10.1007/s13402-023-00861-2
Abstrakt: Purpose: Hepatocellular carcinoma (HCC) responds poorly to immunotherapy, and the durable response rate is 10-20%. Here, we aim to characterize HCC classifications based on lactate genes to identify patients who may benefit from immunotherapy.
Methods: Lactate-related genes were applied for HCC classification in the current study, and lactate Cluster 1 (LC1) and lactate Cluster 2 (LC2) were defined. Differential genes from LC1 and LC2 helped define the following lactate phenotype clusters: lactate phenotype Cluster 1 (LPC1), lactate phenotype Cluster 2 (LPC2) and lactate phenotype Cluster 3 (LPC3). Based on the cluster annotation, the lactate score was defined and analyzed to evaluate the immunotherapy response.
Results: All the classified clusters were analyzed, and they showed different immune signatures. The survival rate of LPC3 was higher than that of LPC2 (LPC3 vs. LPC2, P = 0.027) and LPC1 (LPC3 vs. LPC1, P = 0.027). Then, the lactate score was annotated and confirmed to be effective in predicting responses to immune checkpoint blockade therapy.
Conclusion: In the current study, we developed a classification system for HCC and defined the lactate score, which was validated to be partially effective in estimating responses among tumor patients.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje